Novo Nordisk Announces Semaglutide Price Reduction to Improve Patient Access
Novo Nordisk Drives Semaglutide Price Reduction
Novo Nordisk slashes the US semaglutide list price—or wholesale acquisition cost (WAC)—for Wegovy®, Ozempic®, and Rybelsus® to $675 per month across key doses, effective January 1, 2027. This delivers about 50% and 35% cuts from current levels for Wegovy® and Ozempic®, respectively, targeting access barriers for patients in high-deductible plans or with co-insurance, where out-of-pocket costs link directly to list prices. The strategy enhances affordability without changing direct-to-patient or self-pay options, as detailed in Novo Nordisk’s announcement.
Semaglutide’s Edge Fuels Access Push
Semaglutide stands out in the GLP-1 class with FDA approvals surpassing rivals, covering adult obesity (Wegovy®), type 2 diabetes (Ozempic® and Rybelsus®), chronic kidney disease in type 2 diabetes (Ozempic® injection), and cardiovascular risk reduction (both Wegovy® and Ozempic®). Jamey Millar, executive vice president of US Operations, highlights how this semaglutide price reduction addresses needs for over 100 million US adults with obesity and 35 million with type 2 diabetes, meeting payer and patient calls for lower list prices. Self-pay access via NovoCare® Pharmacy and telehealth remains steady, balancing list price relief with preserved channels for chronic disease leadership.
This list price cut builds on Novo Nordisk’s savings offers and self-pay programs, leaving direct-to-patient pricing intact amid US payer complexities. It covers Wegovy® 2.4 mg injection and 25 mg tablets, Ozempic® 0.5 mg, 1 mg, and 2 mg injections, and Rybelsus® 7 mg or 14 mg tablets—rooted in data on WAC-driven barriers. With over 100 years in diabetes care and 10,000 US employees, the company’s legacy in obesity and diabetes innovations anchors this move toward sustained value.
